Inhibition of IL-8 in the treatment of pain and/or bone loss
Pain associated with a contribution of IL-8 and osteoclasts in a subject is prevented, treated and/or alleviated by the administration of an effective amount of a compound capable of inhibiting or blocking the action of interleukin 8 (IL-8). Methods and compounds for this use are disclosed, as well as a diagnostic method and kit.
1. A method of alleviating joint pain without concurrent synovitis in a subject in need thereof, said method comprising administering to the subject an effective amount of a compound capable of inhibiting or blocking the action of IL-8,
wherein said joint pain without concurrent synovitis is associated with a presence of IL-8 and osteoclasts in the subject,
and
wherein said compound is selected from the group consisting of
reparixin (repertaxin, (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide);
DF 2162 (4-[(1R)-2-amino-1-methyl-2-oxoetthyl]phenyl trifluoromethane sulfonate);
AZD8309 (5-[[(2,3-difluorophenyl)methyl]thio]-7[[(1R)-2-hydroxy-1-methylethyl]amino]-thiazolo[4,5-d]pyrimidin-2(3H-one);
AZD5069 (N-[2-[[2,3-difluorophenyl)methyl]thio]-6-{[(1r,2s)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide);
PD0220245 (N-(3-[2,2′-bithiophen-5-yl]-6,7-dichloro-2-quinoxalinyl)-N,N-diethyl-butane-1,4-diamine dihydrochloride);
SB-332235 (1-(4-chloro-2-hydroxy-3-sulfamoylphenyl)-3-(2,3-dichlorophenyl)urea);
SCH-527123 (navarixin, 2-hydroxy-N,N-dimethyl-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide);
SB-656933 (elubrixin, 1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea);
SB-225002 (N-(2-bromophenyl)-N′-(2-hydroxy-4-nitrophenyl)urea); and
GSK1325756 (danirixin, 1-[4-chloro-2-hydroxy-3-[(3S)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea).
2. The method according to claim 1 , wherein said compound is reparixin (repertaxin, (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide).
3. The method according to claim 1 , wherein said compound is danirixin (1-[4-chloro-2-hydroxy-3-[(3S)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea.
4. A method of alleviating joint pain without concurrent synovitis in a subject in need thereof, said method comprising administering to the subject an effective amount of a compound capable of inhibiting or blocking the action of IL-8,
wherein said joint pain without concurrent synovitis is associated with a presence of IL-8 and osteoclasts in the subject,
wherein IL-8 activation of the osteoclasts is associated with a presence of autoantibodies in said subject,
and
wherein said compound is selected from the group consisting of
reparixin (repertaxin, (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide);
DF 2162 (4-[(1R)-2-amino-1-methyl-2-oxoetthyl]phenyl trifluoromethane sulfonate);
AZD8309 (5-[[(2,3-difluorophenyl)methyl]thio]-7[[(1R)-2-hydroxy-1-methylethyl]amino]-thiazolo[4,5-d]pyrimidin-2(3H-one);
AZD5069 (N-[2-[[2,3-difluorophenyl)methyl]thio]-6-{[(1r,2s)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide);
PD0220245 (N-(3-[2,2′-bithiophen-5-yl]-6,7-dichloro-2-quinoxalinyl)-N,N-diethyl-butane-1,4-diamine dihydrochloride);
SB-332235 (1-(4-chloro-2-hydroxy-3-sulfamoylphenyl)-3-(2,3-dichlorophenyl)urea);
SCH-527123 (navarixin, 2-hydroxy-N,N-dimethyl-3-[[2-[[1 R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide);
SB-656933 (elubrixin, 1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea);
SB-225002 (N-(2-bromophenyl)-N′-(2-hydroxy-4-nitrophenyl)urea); and
GSK1325756 (danirixin, 1-[4-chloro-2-hydroxy-3-[3S)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea).
5. The method according to claim 4 , wherein said autoantibodies are anti-citrullinated protein antibodies (ACPA).
6. The method according to claim 4 , wherein said compound is reparixin (repertaxin, (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide).
7. The method according to claim 4 , wherein said compound is danirixin, 1-[4-chloro-2-hydroxy-3-[(3S)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea.
8. The method according to claim 4 , wherein said autoantibodies are detectable in a sample taken from said subject, using an enzyme-linked immunosorbent assay (ELISA) for qualitative and semi-qualitative determination of IgG antibodies to Cyclic Citrullinated Peptides (CCP).
9. The method according to claim 8 , wherein said subject is suffering from an autoimmune disease selected from rheumatoid arthritis, osteoarthritis, and arthralgia.